Results 201 to 210 of about 2,088,899 (353)

Origin of mutants disputed

Nature, 1988
James J. Bull, Brian Charlesworth, Deborah Charlesworth   +2 more
openaire   +5 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Neurospora crassa Mutants Lacking Argininosuccinase

, 1957
J. R. S. Fincham, Joyce B. Boylen
openalex   +1 more source

A Haploid Mutant in the Jimson Weed, " Datura stramonium " [PDF]

, 1922
A. F. Blakeslee, John Belling, M. E. Farnham, A. Dorothy Bergner   +3 more
openalex   +1 more source

Marker-assisted introgression and characterization of the ph1b mutant in modern US and Australian wheats. [PDF]

Plant Genome
Gyawali Y, Zhang W, Danilova TV, Zhang M, Xu S, Van Sanford D, Carter A, Elias E, Cai X.   +8 more
europepmc   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

The rx3 Gene Contributes to the Evolution of Eye Loss in the Cavefish Astyanax mexicanus. [PDF]

Evol Dev
Shennard D, Sifuentes-Romero I, Ambosie R, Abdelaziz J, Duboue ER, Kowalko JE.   +5 more
europepmc   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

CRISPR/Cas9-targeted smpB mutation revealing roles in biofilm formation, motility, and antibiotic susceptibility in Acinetobacter baumannii. [PDF]

PLoS One
Thavorasak T, Santajit S, Tunyong W, Kong-Ngoen T, Reamtong O, Ampawong S, Saelim N, Srisai T, Aiumurai P, Pumirat P, Chaicumpa W, Indrawattana N.   +11 more
europepmc   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source